Standardized postnatal management of infants with congenital diaphragmatic hernia in Europe: The CDH EURO Consortium Consensus - 2015 Update by Snoek, K.G. (Kitty) et al.
E-Mail karger@karger.com
 Consensus Statement 
 Neonatology 2016;110:66–74 
 DOI: 10.1159/000444210 
 Standardized Postnatal Management of Infants with 
Congenital Diaphragmatic Hernia in Europe: 
The CDH EURO Consortium Consensus – 2015 Update 
 Kitty G. Snoek  a    Irwin K.M. Reiss  a    Anne Greenough  c    Irma Capolupo  e    
Berndt Urlesberger  f    Lucas Wessel  g    Laurent Storme  h    Jan Deprest  d, i    
Thomas Schaible  g    Arno van Heijst  b    Dick Tibboel  a    for the CDH EURO Consortium 
 a   Erasmus MC – Sophia Children’s Hospital, University Medical Center Rotterdam,  Rotterdam , and  b   Radboud University 
Medical Centre,  Nijmegen , The Netherlands;  c   King’s College and  d   University College London Hospitals,  London , UK; 
 e   Bambino Gesu Children’s Hospital,  Rome , Italy;  f   Medical University Graz,  Graz , Austria;  g   Universitätsklinikum Mannheim, 
 Mannheim , Germany;  h   Hôpital Jeanne de Flandre,  Lille , France;  i   University Hospital KU Leuven,  Leuven , Belgium 
nous sildenafil to be considered in CDH patients with severe 
pulmonary hypertension. This article represents the current 
opinion of all consortium members in Europe for the optimal 
neonatal treatment of CDH.  © 2016 The Author(s)
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 Introduction 
 In 2008, the congenital diaphragmatic hernia (CDH) 
EURO Consortium was set up and during a consensus 
meeting drafted a standardized neonatal treatment pro-
tocol to improve outcome and permit comparison of 
outcome data  [1] . Since then the number of participat-
ing centers has increased from 13 to 22 specialized CDH 
centers from all over Europe, and the guidelines from 
2010 have been widely cited. Moreover, after the imple-
mentation of the protocol, the survival rate has increased 
from 67 to 88% in 2 centers. This indicates the impact of 
the original standardized protocol. After 5 years of ad-
ditional research including a multicenter randomized 
clinical trial on initial ventilation strategy (VICI-trial; 
Netherlands Trial Register, NTR 1310), we aimed to up-
date the standardized neonatal treatment protocol for 
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 Abstract 
 In 2010, the congenital diaphragmatic hernia (CDH) EURO 
Consortium published a standardized neonatal treatment 
protocol. Five years later, the number of participating cen-
ters has been raised from 13 to 22. In this article the relevant 
literature is updated, and consensus has been reached be-
tween the members of the CDH EURO Consortium. Key up-
dated recommendations are: (1) planned delivery after a 
gestational age of 39 weeks in a high-volume tertiary center; 
(2) neuromuscular blocking agents to be avoided during ini-
tial treatment in the delivery room; (3) adapt treatment to 
reach a preductal saturation of between 80 and 95% and 
postductal saturation >70%; (4) target PaCO 2 to be between 
50 and 70 mm Hg; (5) conventional mechanical ventilation 
to be the optimal  initial ventilation strategy, and (6) intrave-
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CDH. All recommendations were summarized and 
compared with the protocol in 2010 (online suppl. file; 
see www.karger.com/doi/10.1159/000444210 for all on-
line suppl. material).
 Methods 
 The studies were graded according to the Scottish Intercolle-
giate Guidelines Network (SIGN) criteria  [2] . Five experts individ-
ually primarily determined the levels of evidence on the guidance 
of the SIGN checklist. Differences in opinion were primarily dis-
cussed between the five experts until full consensus was reached, 
and thereafter consensus was reached between all participating cen-
ters. The final consensus statement, therefore, represents the opin-
ion of all participating centers based on the interpretation of the 
recent literature from 2010 to 2015 and includes the main findings 
of the so-called VICI-trial  [3] . A consensus meeting, in which neo-
natologists, pediatric intensivists, gynecologists, prenatal physi-
cians, pediatric surgeons, pediatric cardiologists and general pedia-
tricians from 22 centers participated, was organized to discuss the 
most controversial recommendations. If it was very hard to reach 
consensus on a specific issue, the consortium concurred to investi-
gate those issues in future randomized trials. The levels of evidence 
and grades of recommendation according to the SIGN criteria are 
presented in online supplementary tables 1 and 2, respectively.
 Results 
 Prenatal Management 
 With the increased use of second trimester 2D ultra-
sound and/or MRI, CDH has become a prenatal diagno-
sis. Subsequently, a more detailed expert evaluation 
should be performed to determine the location of the de-
fect, the observed/expected lung-to-head ratio (O/E 
LHR) and the position of the liver (intra-abdominal or 
intrathoracic), in addition to ruling out additional con-
genital anomalies or syndromes  [4, 5] . Associated con-
genital anomalies, such as chromosomal or genitourinary 
anomalies, are present in about 25%  [6] and cardiac 
anomalies in about 20% of cases  [7] . Comprehensive as-
sessment will also include invasive sampling for high-res-
olution genetic testing. Only once a comprehensive as-
sessment has been made can multidisciplinary prenatal 
counseling by clinicians in tertiary centers be offered to 
inform parents about the estimated prognosis after birth. 
Several other additional imaging methods, such as lung 
volumetry, 3D ultrasound and Doppler studies of the pul-
monary vascularization, have been shown in individual 
series to be prognostic for pulmonary hypertension, the 
need for extracorporeal membrane oxygenation (ECMO) 
and survival  [8] . All of these remain research tools, how-
ever, but may ultimately improve the predictive value of 
prenatal testing.
 An experienced tertiary center with a high case volume 
( ≥ 6 CDH patients per year) is the optimal environment 
for the delivery and neonatal treatment of prenatally diag-
nosed CDH fetuses  [9, 10] . Prenatal intervention by fetal 
endoscopic tracheal occlusion (FETO) has been proposed 
to promote lung growth  [11] . Therefore, FETO is being 
evaluated in two randomized clinical trials both in moder-
ate (first interim analysis stage reached; >100 patients ran-
domized) and severe cases (>25 patients randomized) in 
centers in Europe, Australia and Canada (TOTAL trial 
 [12] ; NCT01240057). Current reported survival rates are 
on average around 50%, yet there is a significant impact of 
gestational age at delivery. In the largest cohort study 
where 17.1% of all patients were born under 32 weeks, the 
survival rate was 49.4% for isolated left CDH and 37.9% 
for isolated right CDH  [13] . This suggests that FETO in-
troduces a significant risk for prematurity and all its con-
sequences. It is recommended therefore that – while wait-
ing for the results – FETO should not be performed out-
side the trial  [11] . According to the consensus statement 
of the National Institutes of Health (NIH), CDH fetuses at 
risk for delivery before 34 weeks of gestation should be 
given prenatal steroid therapy.
 Delivery 
 The timing and preferred mode of delivery in CDH 
pregnancies are still controversial. Hutcheon et al.  [14] 
showed that neonatal and infant mortality significantly 
decreased with advancing gestation, from 25 and 36% at 
37 weeks of gestation, respectively, to 17 and 20% at 40 
weeks of gestation, respectively. Moreover, a study from 
Odibo et al.  [15] among 107 CDH cases found that gesta-
tional age at delivery was inversely correlated to the need 
for ECMO. However, Safavi et al.  [16] found no differ-
ence in mortality when dividing gestational age at deliv-
ery categorically as under 37 weeks, 37–38 weeks and 39 
weeks or beyond. Neither did they find a difference in 
mortality between vaginal and cesarean delivery  [16] . In 
the absence of true convincing data it seems intuitive to 
schedule delivery (induced delivery or cesarean section) 
carefully in the best possible conditions also dependent of 
maternal indications, i.e. at 39 weeks or beyond and in the 
presence of the relevant clinicians.
 Recommendations (Prenatal Management and 
Delivery) 
 – Following prenatal diagnosis, disease severity should 
be assessed at an experienced center. This will involve 
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measurement of the O/E LHR and position of the liver 
(grade of recommendation = D). 
 – In case of an anticipated birth prior to 34 weeks of ges-
tation, antenatal steroids should be given (grade of rec-
ommendation = D).  
 – Delivery after a gestational age of 39 weeks in a high-
volume tertiary center should be planned (grade of 
recommendation = D). 
 Delivery Room Management and Treatment in the 
Initial Postnatal Phase 
 Initial treatment and procedures in the delivery room 
are based on the updated Guidelines of the International 
Consensus on Cardiopulmonary Resuscitation and 
Emergency Cardiovascular Care Science with Treatment 
Recommendations  [17] .
 Monitoring and Goal of Treatment 
 Measurements of heart rate, pre- and postductal satu-
rations and intra-arterial blood pressure are recommend-
ed. The key principles are the avoidance of high airway 
pressures and the establishment of adequate perfusion 
and oxygenation (based on preductal arterial saturation, 
SpO 2 measurements). In a study from Dawson et al.  [18] 
in term and preterm healthy neonates, the overall SpO 2 
values at 10 min after birth were median 94% (interquar-
tile range 91–97%) in preterm infants and median 97% in 
term infants (interquartile range 92–98%). Based on ex-
pert opinion, the consortium agreed on preductal SpO 2 
boundaries in the delivery room of 80–95%. In the first 
2 h after birth, preductal SpO 2 levels as low as 70% are ac-
ceptable if they are improving without ventilator changes, 
if organ perfusion is satisfactory, as indicated by a pH 
>7.2, and if ventilation is adequate (PaCO 2 <65 mm Hg, 
8.6 kPa). Since there is growing evidence that room air is 
less harmful than 1.0 fractional inspired oxygen (FiO 2 ) in 
the resuscitation of term infants  [19, 20] , it may be better 
for CDH infants to start with FiO 2 lower than 1.0. The 
aim for preductal saturation is 80–95% after the first hour 
of life. Thus, to avoid hyperoxia, supplemental oxygen 
should be diminished by reducing the oxygen fraction 
when preductal saturation exceeds 95%.
 Intubation and Ventilation 
 The consortium recommends intubating infants with 
prenatally diagnosed CDH immediately after birth as a 
standard of care. The position of the endotracheal tube 
should be confirmed by end-tidal CO 2 monitoring. How-
ever, based on expert opinion, in those infants who are pre-
dicted to have good lung development based on their pre-
natal assessment (e.g. left-sided defect, O/E LHR >50%, and 
liver down), spontaneous breathing could be considered 
instead to prevent ventilator-induced lung injury. Low peak 
pressures, preferably <25 cm H 2 O, are recommended to 
avoid lung damage to the ipsilateral and contralateral lung.
 Sedation and Analgesia/Paralysis for Intubation 
 Carbajal et al.  [21] have studied physiological respons-
es of neonates to awake intubation, and they reported sig-
nificant rises in systemic arterial blood pressure and in-
tracranial pressure, as well as significant decreases in 
heart rate and transcutaneous oxygen saturations. In 166 
infants Caldwell and Watterberg  [22]  found that premed-
ication for intubation significantly attenuated both the 
clinical pain score and the increase in blood glucose as 
markers of acute stress. Moreover, it seems that intuba-
tion success rates progressively improve with premedica-
tion, although in some cases this is not possible due to a 
lack of vascular access  [23] . Murthy et al.  [24] have shown 
no beneficial effects of administration of neuromuscular 
blocking agents immediately after intubation; in fact lung 
compliance deteriorated upon administration.
 Naso- or Orogastric Tube 
 The consortium recommends immediate placing of an 
oro- or nasogastric tube with continuous or intermittent 
suctioning in order to prevent bowel distension and any 
additional ipsilateral lung compression.
 Vascular Access 
 As preductal PaO 2 measurements reflect the level of 
delivered oxygen to the brain, the arterial line should 
preferably be inserted into the right radial artery – also for 
blood sampling and monitoring of the arterial blood pres-
sure. Alternatively, an umbilical arterial line may be 
placed. This is less desirable, however, than a right radial 
artery line because it reflects the postductal situation, but 
on the other hand, it may give more secure longer-term 
arterial access. Each procedure should be performed as 
soon as possible. It is important, however, to prevent fur-
ther agitation from recurrent insertion attempts as this 
may impair postnatal adaptation  [25] .
 Blood Pressure Control 
 Measures to increase the systemic blood pressure may 
minimize the right-to-left shunting. However, there is no 
need to increase blood pressure levels to supranormal val-
ues if the preductal saturation remains above 80%. There-
fore, the consortium recommends maintaining arterial 
blood pressure at normal levels for gestational age if pre-
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ductal saturations remain between 80 and 95%. In the 
case of hypotension and/or poor tissue perfusion, a fluid 
bolus of 10–20 ml/kg NaCl 0.9% should be administered, 
although no more than 2 times. If tissue perfusion and 
blood pressure do not improve, inotropic and/or vaso-
pressor medication should be considered according to lo-
cal practice. Hydrocortisone may be used in the early 
phase for the treatment of hypotension after other treat-
ment has failed  [26] .
 Surfactant 
 There is no rationale for surfactant therapy because in 
CDH patients surfactant amounts are likely to be appro-
priate to lung size  [27] .
 Recommendations 
 – After delivery, the infant should be intubated routine-
ly without bag and mask ventilation (grade of recom-
mendation = D). 
 – The goal of treatment in the delivery room is achieving 
acceptable preductal saturation targets, i.e. between 80 
and 95% (grade of recommendation = D). 
 – Ventilation in the delivery room should be done with 
a peak pressure as low as possible, preferably with 25 
cm H 2 O, or below that (grade of recommendation = 
D). 
 – An oro- or nasogastric tube with continuous or inter-
mittent suction should be placed (grade of recommen-
dation = D). 
 – Arterial blood pressure has to be maintained at a nor-
mal level for gestation. In the case of hypotension and/
or poor tissue perfusion, 10–20 ml/kg NaCl 0.9% 
should be administered 2 times (grade of recommen-
dation = D). 
 – In cases of persistent hypotension after the adminis-
tration of NaCl 0.9%, inotropic and vasopressor agents 
should be considered (grade of recommendation = D). 
 – In CDH infants who are predicted to have good lung 
development based on their prenatal assessment (e.g. 
left-sided defect, O/E LHR >50%, and liver down), 
spontaneous breathing could be considered (grade of 
recommendation = D). 
 – Premedication should be given before intubation if 
possible (grade of recommendation = D). 
 – Neuromuscular blocking agents should be avoided 
during initial treatment in the delivery room (grade of 
recommendation = D). 
 – No routine use of surfactant in either term or preterm 
infants with CDH (grade of recommendation = D). 
 Ventilation Management in the Intensive Care Unit 
 Permissive hypercapnia and ‘gentle ventilation’ have 
been reported to increase survival in neonates with CDH 
 [28, 29] . A ventilation strategy aiming for preductal satu-
ration between 80 and 95%, postductal saturation above 
70% and arterial CO 2 levels between 50 and 70 mm Hg 
(6.9–9.3 kPa, permissive hypercapnia) is well accepted. In 
the first 2 h after birth, preductal SpO 2 levels as low as 70% 
are acceptable provided they are slowly improving and 
organ perfusion is satisfactory (indicated by a pH >7.2), 
and if ventilation is adequate (PaCO 2 <65 mm Hg, 8.6 
kPa). Thereafter, preductal saturation levels are prefera-
bly kept between 85 and 95%. In individual cases, how-
ever, levels down to 80% may be accepted, providing or-
gans are well perfused, as indicated by a pH >7.2, lactate 
levels <5 mmol/l and urinary output >1 ml/kg/h. Post-
ductal saturations should remain above 70%. Oxygen 
toxicity can be avoided by decreasing FiO 2 on the guid-
ance of the saturation levels described above. The optimal 
 initial ventilation strategy was investigated in a collab-
orative initiative from the CDH EURO Consortium 
 (VICI-trial, NTR 1310)  [30] . Although the primary out-
come (death/bronchopulmonary dysplasia at day 28) was 
not significantly different between the two groups, it was 
found that infants initially ventilated by conventional 
mechanical ventilation required a significantly shorter 
duration of ventilation, had less need for inhaled nitric 
oxide (iNO) or sildenafil, had a shorter duration of vaso-
active medication and were less likely to require ECMO 
 [3] . Therefore, the CDH EURO Consortium recom-
mends conventional mechanical ventilation as the initial 
ventilation strategy. Recommendations for initial ventila-
tion settings for pressure-controlled ventilation are sum-
marized below. In the case of weaning, the peak pressure 
should primarily be reduced. Thereafter, frequency or 
PIP/PEEP may be reduced as long as pCO 2 <50 mmHg 
(6.7 kPa). In general, the consortium recommends aim-
ing for a limitation of peak pressure to 25 cm H 2 O or less, 
a PEEP of 3–5 cm H 2 O and adjustment of the ventilator 
rate to obtain PaCO 2 between 50 and 70 mm Hg (6.9–9.3 
kPa). If a PIP of >28 cm H 2 O is necessary to achieve pCO 2 
and saturation levels within the target range, other treat-
ment modalities (such as high-frequency oscillatory ven-
tilation or ECMO) should be considered.
 Chest Radiograph 
 To assess the patient’s initial condition, a chest radio-
graph should be obtained as soon as possible.
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 Recommendations 
 – Conventional mechanical ventilation is the optimal 
 initial ventilation strategy (grade of recommenda-
tion = C). 
 – High-frequency oscillatory ventilation can be used as 
rescue therapy if conventional mechanical ventilation 
fails (grade of recommendation = D). 
 – Adapt ventilation settings to reach a preductal satura-
tion between 80 and 95% and a postductal saturation 
above 70% (grade of recommendation = D). 
 – The target PaCO 2 should be between 50 and 70 mm 
Hg (6.9–9.3 kPa; grade of recommendation = D). 
 – Pressure-controlled ventilation: initial settings are a 
PIP <25 cm H 2 O and a PEEP of 3–5 cm H 2 O; ventila-
tor rate of 40–60/min (grade of recommendation = D). 
 – After stabilization, reduce FiO 2 if the preductal satura-
tion is above 95% (grade of recommendation = D). 
 Further Management in the Intensive Care Unit 
 Sedation and Analgesia 
 A wide range of sedative and analgesic practices has 
been described  [31, 32] . Most centers use opioids such as 
morphine sulfate or fentanyl. Although there is no spe-
cific evidence in infants with CDH, neuromuscular block-
ade is associated with side effects such as hypoxemia – 
and thus should be avoided. Infants should remain se-
dated during mechanical ventilation until weaning form 
mechanical ventilation is commenced.
 Monitoring 
 Heart rate, invasive blood pressure, pO 2 and pCO 2 , 
and pre- and postductal saturation should be monitored 
routinely. A head ultrasound scan should be performed 
at a time when there is little danger of arousing the new-
born. Monitoring the regional cerebral oxygenation satu-
ration with near infrared spectroscopy and transcutane-
ous saturation measurements may be indicated  [33] , al-
though its additional value in CDH infants is not yet clear. 
Sedation and analgesia should be started as soon as ve-
nous access is established. Careful monitoring of the 
blood pressure is then warranted because more fluid vol-
umes or vasoactive drugs may be needed in view of the 
potential adverse hemodynamic effect of sedatives, in 
particular midazolam. Supportive care such as cocooning 
and swaddling is recommended to prevent stress from 
too much noise, light and nociceptive stimulation. The 
infant’s condition should be regularly assessed using val-
idated analgesia and sedation scoring systems, such as the 
COMFORT behavior score  [34] .
 Hemodynamic Management 
 Hemodynamic management should be aimed at 
achieving appropriate end-organ perfusion determined 
by heart rate, urine output and lactate levels. If the heart 
rate is within the normal range  [35] , urine output is over 
1.0 ml/kg/h, lactate concentration is <3 mmol/l and there 
are no other symptoms of poor tissue perfusion, inotropic 
or vasopressor support is not required. Echocardiogra-
phy is indicated if there are signs of poor perfusion or if 
the blood pressure is below the normal level for gestation 
with a preductal saturation below 80%. This may show 
whether the poor perfusion is due to hypovolemia or 
myocardial dysfunction. If there is hypovolemia, saline 
fluid therapy should be given (10–20 ml/kg NaCl 0.9% or 
Ringer lactate up to 2 times during the first 2 h)  [36] . If 
necessary, this should be followed by inotropic and/or va-
sopressor therapy. Hydrocortisone may be used for the 
treatment of hypotension after other treatment has failed.
 Recommendations 
 – Infants should be sedated and be monitored using val-
idated analgesia and sedation scoring systems (grade 
of recommendation = D). 
 – Neuromuscular blocking agents should be avoided if 
possible (grade of recommendation = D). 
 – If symptoms of poor perfusion and/or blood pressure 
below the normal level for gestation occur and are as-
sociated with preductal saturation below 80%, echo-
cardiographic assessment should be performed (grade 
of recommendation = D). 
 – In case of hypovolemia, fluid therapy (10–20 ml/kg 
NaCl 0.9% or Ringer lactate) up to 2 times during the 
first two hours may be given and followed if necessary 
by administration of inotropic and/or vasopressor 
agents (grade of recommendation = D). 
 Pulmonary Hypertension 
 A 2D echocardiography performed within the first 
24 h after birth remains the best modality to (1) rule out 
the presence of cardiac anomalies; (2) assess the right 
heart function, and (3) determine the amount of pulmo-
nary hypertension classified accordingly (less or more 
than 2/3 systemic blood pressure)  [37, 38] . Especially in 
severe cases of pulmonary hypertension, a cardiac ultra-
sound may help to evaluate right ventricular dysfunction 
and/or right ventricular overload, which condition can 
also lead to left ventricular dysfunction  [39] .
 There is no evidence for the usefulness of increasing 
systemic vascular resistance to treat right-to-left shunting, 
but a number of centers from the consortium suggest us-
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ing inotropic or vasopressor agents such as dopamine, do-
butamine and (nor)epinephrine to maintain blood pres-
sure at normal levels for gestation  [40] . If preductal satu-
ration falls below 85% and/or if there are signs of poor 
organ perfusion, treatment of pulmonary hypertension 
should be initiated. The first choice would be iNO, which 
is a pulmonary vasodilator. In neonates with pulmonary 
hypertension of the newborn (PPHN) or severe hypoxic 
respiratory failure, iNO improves oxygenation and de-
creases the need for ECMO  [41, 42] . At an oxygenation 
index of 20 or higher and/or a pre- and postductal satura-
tion difference of 10% or more, iNO may be given for at 
least 1 h. A consistent dose-dependent effect of iNO has 
not yet been shown  [43] . As in one study more infants 
treated with NO needed ECMO  [43] , we recommend 
stopping iNO therapy if no effect is seen after its initiation.
 If there is no or an insufficient response to iNO, intra-
venous prostacyclin, intravenous phosphodiesterase type 
5 inhibitor (sildenafil) or medication involving the endo-
thelin pathway should be considered. These agents have 
been used successfully in treating PPHN in neonates with 
and without CDH  [44, 45] . The effects of treatment may 
be best addressed by repeated cardiac evaluation  [46] . 
This can lead to insufficient filling of the left ventricle and 
thereby to poor systemic perfusion. Reopening of the 
ductus arteriosus with prostaglandin E1 may protect the 
right ventricle from excessive overload due to increased 
afterload  [47] . Phosphodiesterase-3 inhibitor (Milri-
none) was investigated in only 6 CDH patients by Patel et 
al.  [48] . Right ventricular function and oxygenation index 
significantly improved. Sildenafil has been used in the 
treatment of pulmonary hypertension in infants with 
CDH. Intravenous sildenafil has recently become avail-
able, but its use has not yet been FDA approved.
 Recommendations 
 – Perform echocardiography within the first 24 h after 
birth to rule out structural cardiac anomalies (grade of 
recommendation = D). 
 – Blood pressure support should be given to maintain 
arterial blood pressure levels at normal levels for gesta-
tion (grade of recommendation = D). 
 – iNO administration for at least 1 h in a dose of 10–20 
ppm should be considered if there is evidence of extra-
pulmonary right-to-left shunting and the oxygenation 
index is above 20 and/or the saturation difference is 
more than 10% (grade of recommendation = D). 
 – In nonresponders iNO should be stopped. iNO re-
sponders are defined as follows: a decline of 10–20% in 
the pre-postductal saturation difference, or an increase 
of 10–20% of PaO 2 , or improvement in hemodynamic 
parameters meaning a 10% increase in mean blood 
pressure, or a decrease in lactate levels (grade of rec-
ommendation = D). 
 – Intravenous sildenafil should be considered in CDH 
patients with severe pulmonary hypertension (grade 
of recommendation = D). 
 – In case of suprasystemic pulmonary artery pressure 
and right-to-left shunting through the foramen ovale, 
intravenous prostaglandin E1 should be considered 
(grade of recommendation = D). 
 Extracorporeal Membrane Oxygenation 
 The benefit of ECMO in the treatment of infants with 
CDH remains unclear. The ELSO registry showed a sur-
vival rate of 51% of patients with CDH who required 
ECMO  [49] . The use of ECMO has decreased in recent 
years  [50] ; it is more used for preoperative stabilization, 
and the preferred method (venoarterial vs. venovenous) 
is still being debated. The VICI-trial showed no difference 
in survival between patients born in ECMO centers and 
patients born in non-ECMO centers  [3] .
 Recommendations 
 – Criteria for ECMO (grade of recommendation = D): 
  •  Inability to maintain preductal saturations >85% or 
postductal saturations >70%. 
  •  Increased PaCO 2 and respiratory acidosis with pH 
<7.15 despite optimization of ventilator management. 
  •  Peak inspiratory pressure >28 cm H 2 O or mean air-
way pressure >17 cm H 2 O is required to achieve sat-
uration >85%. 
  •  Inadequate oxygen delivery with metabolic acidosis as 
measured by elevated lactate  ≥ 5 mmol/l and pH <7.15. 
  •  Systemic hypotension, resistant to fluid and inotro-
pic therapy, resulting in urine output <0.5 ml/kg/h 
for at least 12–24 h. 
  •  Oxygenation index  ≥ 40 present for at least 3 h. 
 Surgical Repair 
 Surgery should be performed electively. The effect of 
hospital volume on mortality is unclear. While a large study 
(2,203 infants) concluded that hospitals with a high volume 
of CDH repair have lower in-hospital mortality  [51] , a 
more recent study in 3,738 infants showed no difference in 
mortality between lower and higher surgical volume cen-
ters  [52] . Controversies about the exact timing of the surgi-
cal repair in patients on ECMO remain  [53] . A recent study 
from Partridge et al.  [54]  showed improved outcomes with 
surgical repair after ECMO, i.e. a higher likelihood of sur-
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vival, less surgical bleeding and shorter duration of ECMO. 
A relative small study (n = 46) from Fallon et al.  [55] found 
that repair within the first 72 h of ECMO correlated with a 
shorter duration of ECMO, less circuit complications and 
a trend towards improved survival.
 The routine use of a chest tube postoperatively to drain 
the effusion filling the pleural cavity has been abandoned. 
This does not preclude its use in individual cases to drain 
an effusion that is symptomatic, for example due to chy-
lothorax existing before surgery.
 The optimal surgical technique also remains under de-
bate. Minimal access surgery is gaining ground on the 
open approach (thoracotomy or laparotomy)  [56] . Mini-
mal access surgery has esthetic advantages and may be 
performed in patients with a left-sided defect and liver 
down, but carries a significantly higher risk of recurrence 
 [56, 57] . There is also concern about absorption of CO 2 
used for insufflation in minimal access surgery  [58] , and 
CO 2 insufflation pressures should therefore be mini-
mized. A meta-analysis from Lansdale et al.  [59] showed 
that thoracoscopic repair had greater recurrence rates 
and operative times but similar survival and patch usage 
compared with open surgery. Recently, Costerus et al. 
 [60] concluded that thoracoscopic primary closure seems 
a safe and effective procedure, but efficacy of thoraco-
scopic patch repair has not been established. To allow for 
better comparison of patient groups between studies it is 
recommended to record the diaphragmatic defect size in 
all surgeries  [37] .
 Recommendations 
 – Surgical repair of the diaphragmatic defect should be 
performed after clinical stabilization, defined as fol-
lows (grade of recommendation = D): 
 •  Mean arterial blood pressure normal for gestation. 
  •  Preductal saturation levels of 85–95% on FiO 2 below 
50%. 
 •  Lactate below 3 mmol/l. 
  •  Urine output more than 1 ml/kg/h. 
 – No routine chest tube placement postoperatively 
(grade of recommendation = D). 
 – Repair can be performed while the patient is on ECMO 
(grade of recommendation = D). 
 Fluid Management, Parenteral Feeding, Entering 
Enteral Feeding and Gastroesophageal Reflux 
 Restrictive fluid management in the first 24 h after 
birth consists of 40 ml/kg/day of fluids including medica-
tion, with additional saline volume top-up for intravascu-
lar filling in the case of inadequate tissue perfusion or 
hypotension. Parenteral nutrition only is allowed until 
surgical repair and until postoperative enteral feeding has 
been achieved. Gastroesophageal reflux may be treated 
both by antireflux medication and by surgical interven-
tion  [61] . Maier et al.  [62] did not show evidence for prof-
it beyond the first year of life after prophylactic Thal pro-
cedure at primary CDH repair. Diuretics should be given 
in the case of persisting positive fluid balance without hy-
povolemia, aiming for diuresis of >1 ml/kg/h  [63] .
 Recommendations 
 – 40 ml/kg/day saline including medication for the first 
24 h after birth; increase intake thereafter (grade of 
recommendation = D). 
 – Diuretics should be considered in the case of persisting 
positive fluid balance; aim for a diuresis >1 ml/kg/h 
(grade of recommendation = D). 
 – Preventive antireflux therapy should be started in 
combination with enteral feeding (grade of recom-
mendation = D). 
 – Preoperatively, patients should only receive parenteral 
nutrition (grade of recommendation = D). 
 Conclusion 
 The European task force for CDH (CDH EURO Con-
sortium) has agreed on an updated protocol for standard-
ized postnatal treatment guidelines. Although it is emi-
nence-based medicine and many recommendations are 
level D, we think that a consensus of many specialized 
centers on the use of a standardized treatment protocol 
will contribute to making more valid comparisons of pa-
tient data in ongoing and future multicenter prospective 
clinical studies.
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